

CURRICULUM VITAE

Paul H. Seigel, M.D., F.A.C.C.
8950 N. Kendall Drive, Suite 601
Miami, Florida 33176
(305) 279-4500

Date of Birth: February 11, 1951
Marital Status: Married
Health: Excellent

PROFESSIONAL AFFILIATION:

Attending Physician
Baptist Hospital of Miami
8900 N. Kendall Drive
Miami, Florida 33176

CURRENT LICENSE:

National Board of Medical Examiners
License - Number 0040215

EDUCATION:

Medical College of Virginia
M.D. - June 1977

State University of New York at Binghamton
B.A. - May 1973

POST GRADUATE TRAINING:

Fellowship in Cardiovascular Medicine
College of Medicine and Dentistry of New Jersey
Newark Beth Israel Hospital
July 1980 - June 1982

Residency in Internal Medicine
University of Maryland
Baltimore, Maryland
July 1978 - June 1980

POST GRADUATE TRAINING CONTINUED...

Internship in Internal Medicine

University of Maryland
Baltimore, Maryland
July 1977 - June 1978

INVESTIGATIONS - RESEARCH:

Cardiovascular Research Center of South Florida

INVEST (Knoll Pharmaceuticals). Principal Investigator. This is an international clinical trial comparing a calcium antagonist (Verapamil Sinus rhythm) with a non-calcium antagonist treatment strategy (Atenolol) for the control of hypertension in patients with coronary artery disease.

T.N.T. (Treating to New Targets) Parke-Davis/Pfizer. Principal Investigator. This study is to assess the CHD event reduction efficacy and safety of low-density lipoprotein cholesterol lowering to achieve LDL-C targets beyond currently recommended minimums when compared to only achieving the minimum.
Drug Used: Atorvastatin 10 mg up to 80 mg in the double-blind period.

CAMELOT (Pfizer, Inc). Principal Investigator. Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis.

GUSTO IV (Eli Lilly and Co). Principal Investigator. This is a post-MI study through the Cleveland Clinic.

BRAVO: Blockade of the GP IIB/IIA Receptor to Avoid Vascular Occlusion. Principal Investigator.

PRESTO: Prevention of REStenosis by Tranilast and its Outcomes. Principal Investigator. A phase III Double blind Placebo Controlled Trial of three doses of Tranilast (Protocol 004).

MOXON TRIAL (Covance). Principal Investigator.

STARSHIP (AstraZeneca) A 6 week, Randomized, open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atirvastatin in the Treatment of Hypercholesterolemia in Hispanic Subjects.

INVESTIGATIONS – RESEARCH (continued):

ACTIVATE (SankyoPharma Development) A Randomized, Double-Blind placebo Controlled Study of the Efficacy and Safety of the ACAT inhibitor CS-505 versus Placebo for Reducing the Progression of Atherosclerosis in Subjects with Known Coronary Artery Disease Using Ultrasound (IVUS).

EVEREST (Otsuka Pharmaceuticals) A Randomized, Double-blind Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure.

CHARISMA (Sanofinsynthelabo and Bristol Myers Squibb Co.) Clopidogrel For High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance.

CP-529, 414 (Pfizer) A Randomized, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin in Patients with Angiographically Documented Coronary Artery Disease.

LUNAR (AstraZeneca) A 12-Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes.

NEB 302 (Bertek Pharmaceuticals) A Double-blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Dosing Study Evaluating the Effects of Nebivolol on Blood Pressure in Patients with Mild to Moderate Hypertension.

NEB 306 (Bertek Pharmaceuticals) A Multi-Center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients with Mild to Moderate Hypertension.

NEB 323 (Bertek Pharmaceuticals) A Multi-Center, Open Extension Study to Assess the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients with Mild to Moderate Hypertension.

COMPELL (Kos Pharmaceuticals) An Open-Label, Comparative Efficacy Evaluation of Lipid Levels when Treated with Niaspan and Statin or Other Lipid-Modifying Therapies.

INVESTIGATIONS – RESEARCH (continued):

MDT3-003 (Labopharm) A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once a day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain due to Osteoarthritis of the Knee.

CERTIFICATIONS AND EXAMS:

Diplomate of the American Board of Internal Medicine -
September 9, 1980 - #75162

Diplomate of the American Board of Cardiovascular Medicine -
November 9, 1983 - #75162

Diplomate of National Board of Medical Examiners -
July 1, 1978

PRIVATE PRACTICE EXPERIENCE:

James Bierfeld, M.D.
Miami, Florida
1983 – 1985

Solo Practice
Miami, Florida
1985 – 1990

Associates in Cardiology
Miami, Florida
1990 - March 1997

Miami Cardiology Group
Managing Partner
8950 N. Kendall Drive, Suite 601
Miami, Florida 33176
March 1997 – Present

PROFESSIONAL ORGANIZATIONS:

American College of Cardiology

REFERENCES:

Furnished Upon Request